Temat: "rilpivirine" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment.
Autorzy:: Zhang C; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Yang Y; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Gan S; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Ren A; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Liutiao Road 2#, Changchun 130061, China.
Zhou YB; National Center for Drug Screening, State key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, SSIP Healthcare and Medicine Demonstration Zone, Zhongshan Tsuihang New District, Zhongshan 528400, China.
Li J; National Center for Drug Screening, State key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, SSIP Healthcare and Medicine Demonstration Zone, Zhongshan Tsuihang New District, Zhongshan 528400, China.
Xiang DJ; Xishan People's Hospital of Wuxi City, Wuxi 214105, China.
Wang WL; School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.; Pokaż więcej
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2023 Aug 21; Vol. 28 (16). Date of Electronic Publication: 2023 Aug 21.
Typ publikacji:: Journal Article
MeSH Terms:: Rilpivirine*
Lung Neoplasms*
Humans ; HeLa Cells ; Carbazoles/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Autorzy:: Nasreddine R; Saint-Pierre University Hospital, Brussels, Belgium.
Yombi JC; Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Darcis G; Liège University Hospital, Liège, Belgium.
Florence E; Institute of Tropical Medicine, Antwerp, Belgium.
Allard SD; Universitair Ziekenhuis Brussel, Brussels, Belgium.
De Scheerder MA; Ghent University Hospital, Ghent, Belgium.
Henrard S; University Clinics of Brussels - Erasme Hospital, Brussels, Belgium.
Demeester R; University Hospital of Charleroi, Lodelinsart, Belgium.
Messiaen P; Jessa Hospital, Hasselt, Belgium.
Ausselet N; UCL University Hospital Namur-Godinne, Yvoir, Belgium.
Loeckx M; ViiV Healthcare, Belgium.
Delforge M; Saint-Pierre University Hospital, Brussels, Belgium.
De Wit S; Saint-Pierre University Hospital, Brussels, Belgium.; Pokaż więcej
Corporate Authors:: Belgian Research on AIDS and HIV Consortium (BREACH)
Źródło:: HIV medicine [HIV Med] 2023 Mar; Vol. 24 (3), pp. 267-278. Date of Electronic Publication: 2022 Aug 08.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Lamivudine*/therapeutic use
Rilpivirine*/therapeutic use
Female ; Humans ; Male ; Middle Aged ; Belgium ; Drug Combinations ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
Autorzy:: Adachi E; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. .
Saito M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Otani A; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Koga M; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Yotsuyanagi H; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.; Pokaż więcej
Źródło:: AIDS research and therapy [AIDS Res Ther] 2024 Jan 03; Vol. 21 (1), pp. 1. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:: Journal Article
MeSH Terms:: HIV Infections*/drug therapy
Anti-HIV Agents*/therapeutic use
Humans ; Rilpivirine/therapeutic use ; Anti-Retroviral Agents/therapeutic use ; Biomarkers ; Cholesterol/therapeutic use ; Lipids

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting.
Autorzy:: Maggi P; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, 81100 Caserta, Italy.
Ricci ED; Fondazione ASIA Onlus, 20090 Buccinasco, Italy.
Martinelli CV; AOU Infectious and Tropical Diseases, Careggi Hospital, 50134 Florence, Italy.
De Socio GV; Unit of Infectious Diseases, Santa Maria Hospital,06156 Perugia, Italy.
Squillace N; Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Molteni C; Unit of Infectious Diseases, A. Manzoni Hospital, 23900 Lecco, Italy.
Masiello A; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, 81100 Caserta, Italy.
Orofino G; Division I of Infectious and Tropical Diseases, ASL Città di Torino, 10149 Torino, Italy.
Menzaghi B; Unit of Infectious Diseases, ASST della Valle Olona, 21052 Busto Arsizio, Italy.
Bellagamba R; National Institute for Infectious Diseases Lazzaro Spallanzani Institute for Hospitalization and Care Scientific, Lazio, 00161 Roma, Italy.
Vichi F; SOC 1 USLCENTRO Firenze, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, 50012 Florence, Italy.
Celesia BM; Unit of Infectious Diseases, Garibaldi Hospital, 95124 Catania, Italy.
Madeddu G; Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Pellicanò GF; Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, 98125 Messina, Italy.
Carleo MA; Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, 80131 Naples, Italy.
Cascio A; Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy.
Parisini A; Department of Infectious Diseases, Galliera Hospital, 16128 Genoa, Italy.
Taramasso L; Clinic of Infectious Diseases, IRCCS Policlinico San Martino Hospital, University of Genoa, 16132 Genoa, Italy.
Valsecchi L; 1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, 20157 Milan, Italy.
Calza L; Infectious Diseases Unit, IRCCS Policlinico Sant' Orsola, Department of Medical Surgical Science, University of Bologna, 40138 Bologna, Italy.
Rusconi S; Infectious Diseases Unit, Ospedale Civile di Legnano, ASST Ovest Milanese, and DIBIC Luigi Sacco, Università degli Studi di Milano, 20025 Legnano, Italy.
Sarchi E; Infectious Diseases Unit, Santi Antonio e Biagio e Cesare Arrigo Hospital, 15121 Alessandria, Italy.
Martini S; Infectious Disease Unit, University Hospital Luigi Vanvitelli, 80138 Naples, Italy.
Bargiacchi O; Unit of Infectious Diseases, Ospedale Maggiore della Carità, 28100 Novara, Italy.
Falasca K; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, 66100 Chieti, Italy.
Cenderello G; Department of Infectious Diseases, Sanremo Hospital, 18038 Sanremo, Italy.
Ferrara S; Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Di Biagio A; Clinic of Infectious Diseases, IRCCS Policlinico San Martino Hospital, University of Genoa, 16132 Genoa, Italy.
Bonfanti P; Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.; School of Surgery and Medicine, University of Milano-Bicocca, 20126 Milan, Italy.; Pokaż więcej
Corporate Authors:: CISAI Study Group
Źródło:: Viruses [Viruses] 2023 Jul 23; Vol. 15 (7). Date of Electronic Publication: 2023 Jul 23.
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Humans ; Rilpivirine/therapeutic use ; Rilpivirine/pharmacology ; Transaminases ; Anti-Retroviral Agents/therapeutic use ; Lipoproteins, LDL ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology.
Autorzy:: Pereira M; OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), 4200-450 Porto, Portugal.; , Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.; Institute of Biomedical Sciences Abel Salazar (ICBAS), Universidade do Porto (UP), 4050-313 Porto, Portugal.
Vale N; OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), 4200-450 Porto, Portugal.; , Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.; Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 02; Vol. 24 (3). Date of Electronic Publication: 2023 Feb 02.
Typ publikacji:: Journal Article; Review
MeSH Terms:: HIV-1*
Zika Virus*
HIV Infections*/drug therapy
Zika Virus Infection*/drug therapy
Anti-HIV Agents*/pharmacology
Humans ; Rilpivirine/pharmacology ; Rilpivirine/therapeutic use ; Anti-Retroviral Agents/therapeutic use ; Reverse Transcriptase Inhibitors/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Autorzy:: Giacomelli A; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Conti F; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Pezzati L; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Oreni L; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
Ridolfo AL; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Morena V; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Bonazzetti C; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Pagani G; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.; Infectious Diseases Unit, Legnano General Hospital, ASST Ovest Milanese, Via G.B. Grassi 74, 20157, Milan, Italy.
Formenti T; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
Galli M; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy.
Rusconi S; Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy. .; III Infectious Diseases Unit, Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Luigi Sacco Hospital, Legnano (MI), Italy. .; Pokaż więcej
Źródło:: BMC infectious diseases [BMC Infect Dis] 2021 Jun 22; Vol. 21 (1), pp. 595. Date of Electronic Publication: 2021 Jun 22.
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents/*therapeutic use
Dideoxynucleosides/*therapeutic use
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/*therapeutic use
Emtricitabine, Rilpivirine, Tenofovir Drug Combination/*therapeutic use
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Lamivudine/*therapeutic use
Oxazines/*therapeutic use
Piperazines/*therapeutic use
Pyridones/*therapeutic use
Adult ; Anti-HIV Agents/metabolism ; Body Weight/drug effects ; Cohort Studies ; Dideoxynucleosides/metabolism ; Drug Combinations ; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/metabolism ; Emtricitabine, Rilpivirine, Tenofovir Drug Combination/metabolism ; Female ; Heart Disease Risk Factors ; Heterocyclic Compounds, 3-Ring/metabolism ; Humans ; Italy/epidemiology ; Lamivudine/metabolism ; Lipid Metabolism/drug effects ; Lipids/blood ; Male ; Middle Aged ; Oxazines/metabolism ; Piperazines/metabolism ; Pyridones/metabolism ; Retrospective Studies ; Tablets/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Autorzy:: Parker B; Health Economics and Outcomes Research Ltd, Pontprennau, Cardiff, United Kingdom.
Ward T; Health Economics and Outcomes Research Ltd, Pontprennau, Cardiff, United Kingdom.
Hayward O; Health Economics and Outcomes Research Ltd, Pontprennau, Cardiff, United Kingdom.
Jacob I; Health Economics and Outcomes Research Ltd, Pontprennau, Cardiff, United Kingdom.
Arthurs E; Health Economics & Outcomes Research, GlaxoSmithKline, Toronto, Ontario, Canada.
Becker D; Quadrant Health Economics Inc, Cambridge, Ontario, Canada.
Anderson SJ; Value Evidence and Outcomes, GlaxoSmithKline, Brentford, Middlesex, United Kingdom.
Chounta V; Global Health Outcomes, ViiV Healthcare Ltd, Brentford, Middlesex, United Kingdom.
Van de Velde N; Global Health Outcomes, ViiV Healthcare Ltd, Brentford, Middlesex, United Kingdom.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Feb 02; Vol. 16 (2), pp. e0245955. Date of Electronic Publication: 2021 Feb 02 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cost-Benefit Analysis*
Models, Statistical*
HIV Infections/*drug therapy
HIV-1/*physiology
Pyridones/*pharmacology
Rilpivirine/*pharmacology
Treatment Adherence and Compliance/*statistics & numerical data
Anti-HIV Agents/economics ; Anti-HIV Agents/pharmacology ; Anti-HIV Agents/therapeutic use ; Drug Interactions ; HIV Infections/transmission ; HIV-1/drug effects ; Humans ; Pyridones/economics ; Pyridones/therapeutic use ; Rilpivirine/economics ; Rilpivirine/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens.
Autorzy:: Maggi P; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy.
Ricci ED; Fondazione ASIA Onlus, Via Garibaldi, 13, Buccinasco, 20090, MI, Italy. .
Cicalini S; National Institute for Infectious Diseases Lazzaro Spallanzani Institute for Hospitalization and Care Scientific, Roma, Lazio, Italy.
Pellicanò GF; Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, Messina, Italy.
Celesia BM; Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy.
Vichi F; Unit of Infectious Diseases, USLCENTRO FIRENZE, Santa Maria Annunziata Hospital, Florence, Italy.
Cascio A; Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Sarchi E; Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.
Orofino G; Division I of Infectious and Tropical Diseases, ASL Città di Torino, Torino, Italy.
Squillace N; Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Madeddu G; Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
De Socio GV; Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy.
Bargiacchi O; Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy.
Molteni C; Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy.
Masiello A; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy.
Saracino A; Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari Aldo Moro, Bari, Italy.
Menzaghi B; Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio (VA), Busto Arsizio VA, Italy.
Falasca K; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy.
Taramasso L; Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy.
Di Biagio A; Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy.
Bonfanti P; Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza - University of Milano-Bicocca, Monza, Italy.; Pokaż więcej
Źródło:: BMC infectious diseases [BMC Infect Dis] 2023 Apr 14; Vol. 23 (1), pp. 227. Date of Electronic Publication: 2023 Apr 14.
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Humans ; Rilpivirine/therapeutic use ; Reverse Transcriptase Inhibitors/therapeutic use ; Lipids

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Long-Acting Antiretroviral Drug Therapy in Adolescents: Current Status and Future Prospects.
Autorzy:: Freij BJ; Pediatric Infectious Diseases Section, Beaumont Children's Hospital, Royal Oak, Michigan, USA.; Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.
Aldrich AM; Pediatric Infectious Diseases Section, Corewell Health Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.; Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, Lansing, Michigan, USA.; Michigan State University College of Osteopathic Medicine, Lansing, Michigan, USA.
Ogrin SL; Pediatric Infectious Diseases Section, Corewell Health Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.
Olivero RM; Pediatric Infectious Diseases Section, Corewell Health Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.; Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, Lansing, Michigan, USA.; Pokaż więcej
Źródło:: Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2023 Feb 09; Vol. 12 (1), pp. 43-48.
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents*
HIV Infections*/drug therapy
Humans ; Adolescent ; Pharmaceutical Preparations ; Rilpivirine/adverse effects ; Anti-Retroviral Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
Autorzy:: D'Amico R; ViiV Healthcare, Durham, North Carolina, USA.
Cenoz Gomis S; ViiV Healthcare, Madrid, Spain.
Moodley R; ViiV Healthcare, Brentford, UK.
Van Solingen-Ristea R; Janssen Pharmaceutica, Beerse, Belgium.
Baugh B; Janssen Pharmaceutica, Raritan, New Jersey, USA.
Van Landuyt E; Janssen Pharmaceutica, Beerse, Belgium.
Van Eygen V; Janssen Pharmaceutica, Beerse, Belgium.
Min S; ViiV Healthcare, Durham, North Carolina, USA.
Cutrell A; ViiV Healthcare, Durham, North Carolina, USA.
Foster C; Imperial College NHS Healthcare Trust, London, UK.
Chilton D; Guys and St Thomas NHS Healthcare Trust, London, UK.
Allard SD; HIV Reference Center Universitair Ziekenhuis Brussel, Brussels, Belgium.
Ruiter A; ViiV Healthcare, Brentford, UK.; Pokaż więcej
Źródło:: HIV medicine [HIV Med] 2023 Feb; Vol. 24 (2), pp. 202-211. Date of Electronic Publication: 2022 Aug 09.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections*/drug therapy
HIV-1*/genetics
Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Seropositivity*/drug therapy
Humans ; Rilpivirine/pharmacology ; Rilpivirine/therapeutic use ; Compassionate Use Trials ; Viremia/drug therapy ; Anti-Retroviral Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.
Autorzy:: Islam, Saiful (AUTHOR)
Rahaman, Muhammed H. (AUTHOR)
Yu, Mingfeng (AUTHOR)
Noll, Benjamin (AUTHOR)
Martin, Jennifer H. (AUTHOR)
Wang, Shudong (AUTHOR)
Head, Richard (AUTHOR); Pokaż więcej
Źródło:: Cancers. Feb2023, Vol. 15 Issue 4, p1044. 21p.

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Autorzy:: Dueñas-Gutiérrez C; Infectious Diseases Division, Hospital Universitario Clínico de Valladolid, 47003 Valladolid, Spain.
Buzón L; Infectious Diseases Division, Hospital Universitario de Burgos, 09006 Burgos, Spain.
Pedrero-Tomé R; Infanta Leonor University Hospital Research and Innovation Foundation, 28031 Madrid, Spain.
Iribarren JA; Infectious Diseases Department, Hospital Universitario de Donostia, 20014 San Sebastián, Spain.
De Los Santos I; Infectious Diseases Division, Hospital Universitario de La Princesa, 28006 Madrid, Spain.
De la Fuente S; Infectious Diseases Division, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain.
Pousada G; Infectious Diseases Division, Hospital Universitario de Txagorritxu, 01009 Vitoria, Spain.
Moran MA; Infectious Diseases Division, HospitalÁlvaro Cunqueiro, 36312 Vigo, Spain.
Moreno E; Infectious Diseases Division, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Ferreira E; Infectious Diseases Division, Hospital de Segovia, 47002 Segovia, Spain.
Gómez J; Infectious Diseases Division, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.
Troya J; Internal Medicine Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain.; Pokaż więcej
Źródło:: Viruses [Viruses] 2023 Apr 10; Vol. 15 (4). Date of Electronic Publication: 2023 Apr 10.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: HIV Infections*/drug therapy
HIV-1*
Anti-HIV Agents*/adverse effects
HIV Seropositivity*
Drug-Related Side Effects and Adverse Reactions*/epidemiology
Humans ; Lamivudine/adverse effects ; Retrospective Studies ; Rilpivirine/adverse effects ; Heterocyclic Compounds, 3-Ring/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study.
Autorzy:: De Vito A; Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Ricci E; Fondazione ASIA Onlus, Buccinasco, 20090 Milan, Italy.
Menzaghi B; Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio Hospital, 21052 Busto Arsizio, Italy.
Orofino G; Unit of Infectious Diseases, 'Divisione A', Amedeo di Savoia Hospital, 10149 Torino, Italy.
Martinelli CV; SOD Malattie Infettive e Tropicali, AOU Careggi, 50100 Firenze, Italy.
Squillace N; Infectious Diseases Clinic, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, 20126 Monza, Italy.
Taramasso L; Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, 16132 Genoa, Italy.
De Socio GV; Clinic of Infectious Diseases, Department of Medicine, Azienda Ospedaliera di Perugia, Santa Maria Hospital, 06100 Perugia, Italy.
Molteni C; Infectious Disease Unit, Ospedale A. Manzoni, 23900 Lecco, Italy.
Valsecchi L; Infectious Disease Unit (I Division), ASST Fatebenefratelli Sacco, 20157 Milan, Italy.
Costa C; Infectious Diseases Department, SOC 1, USLCENTROFIRENZE, Santa Maria Annunziata Hospital, 50012 Florence, Italy.
Celesia BM; Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi, 95124 Catania, Italy.
Parruti G; Infectious Diseases Unit, Pescara General Hospital, 66020 Pescara, Italy.
Pellicanò GF; Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age 'G. Barresi', University of Messina, 98122 Messina, Italy.
Sarchi E; Infectious Diseases Unit, SS. Antonio e Biagio e Cesare Arrigo Hospital, 15121 Alessandria, Italy.
Cascio A; Infectious and Tropical Diseases Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy.
Cenderello G; Infectious Disease Unit, Sanremo Hospital, 18038 Sanremo, Italy.
Falasca K; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University 'G. d' Annunzio' Chieti-Pescara, 66100 Chieti, Italy.
Di Biagio A; Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, 16132 Genoa, Italy.
Bonfanti P; Infectious Diseases Clinic, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, 20126 Monza, Italy.
Madeddu G; Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.; Pokaż więcej
Źródło:: Viruses [Viruses] 2023 Mar 10; Vol. 15 (3). Date of Electronic Publication: 2023 Mar 10.
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents*
HIV Infections*/drug therapy
Humans ; Retrospective Studies ; Lopinavir/therapeutic use ; Rilpivirine/therapeutic use ; Cohort Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Autorzy:: Hidalgo-Tenorio C; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.
Vinuesa D; Unit of Infectious Diseases, San Cecilio University Hospital, Biohealth Research Institute, IBS-Granada, 18012 Granada, Spain.
García-Vallecillos C; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.
Muñoz-Medina L; Unit of Infectious Diseases, San Cecilio University Hospital, Biohealth Research Institute, IBS-Granada, 18012 Granada, Spain.
Sequera S; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.
Javier R; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.
López-Ruz MÁ; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.
Sadyrbaeva-Dolgova S; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.
Pasquau J; Unit of Infectious Diseases, Virgen de las Nieves University Hospital, Biohealth Research Institute, IBS-Granada, 18014 Granada, Spain.; Pokaż więcej
Źródło:: Viruses [Viruses] 2022 Nov 25; Vol. 14 (12). Date of Electronic Publication: 2022 Nov 25.
Typ publikacji:: Observational Study; Multicenter Study; Journal Article
MeSH Terms:: Anti-HIV Agents*/adverse effects
HIV Infections*/drug therapy
Humans ; Male ; Middle Aged ; Female ; Rilpivirine/adverse effects ; Heterocyclic Compounds, 3-Ring/adverse effects ; Lipids ; Tablets/therapeutic use ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Two cases of drug induced hypersensitivity to dolutegravir-rilpivirine fixed-dose combination: A case report.
Autorzy:: Del Fabro G; Department of Infectious and Tropical Diseases, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Mileto P; Allergy Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Castelli F; Department of Infectious and Tropical Diseases, ASST Spedali Civili, University of Brescia, Brescia, Italy.
Quiros-Roldan E; Department of Infectious and Tropical Diseases, ASST Spedali Civili, University of Brescia, Brescia, Italy.; Pokaż więcej
Źródło:: The International journal of risk & safety in medicine [Int J Risk Saf Med] 2023; Vol. 34 (2), pp. 155-159.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Drug Hypersensitivity*
Excipients*/adverse effects
Anti-HIV Agents*/adverse effects
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Humans ; Male ; Female ; Adult ; Aged ; Rilpivirine/therapeutic use ; Drug Combinations ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
Autorzy:: Kilcrease C; Department of Clinical Pharmacy, Johns Hopkins Hospital, Baltimore, MD, USA.; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Yusuf H; Department of Pediatrics, Division of Pediatric Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Park J; Department of Pediatrics, Division of General Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Powell A; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Rn LJ; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Rn JO; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lmsw BD; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Weld ED; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.; Department of Medicine, Division of Clinical Pharmacology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Dooley KE; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Arrington-Sanders R; 7Department of Pediatrics, Division of Adolescent and Young Adult Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Agwu AL; Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA. .; Department of Pediatrics, Division of Pediatric Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA. .; Pediatric Adolescent Young Adult HIV/AIDS Program Medical Director, Accessing Care Early (ACE) Clinic, Johns Hopkins University School of Medicine, 21287, Baltimore, MD, USA. .; Pokaż więcej
Źródło:: AIDS research and therapy [AIDS Res Ther] 2022 Nov 26; Vol. 19 (1), pp. 56. Date of Electronic Publication: 2022 Nov 26.
Typ publikacji:: Case Reports; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: HIV Infections*/drug therapy
Adolescent ; Young Adult ; Female ; Humans ; Child ; Adult ; Anti-Retroviral Agents/therapeutic use ; Viral Load ; Viremia/drug therapy ; Rilpivirine/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Autorzy:: Garris CP; ViiV Healthcare, Durham, North Carolina, USA.
Czarnogorski M; ViiV Healthcare, Durham, North Carolina, USA.
Dalessandro M; ViiV Healthcare, Collegeville, Pennsylvania, USA.
D'Amico R; ViiV Healthcare, Durham, North Carolina, USA.
Nwafor T; ViiV Healthcare, Durham, North Carolina, USA.
Williams W; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Merrill D; ViiV Healthcare, Durham, North Carolina, USA.
Wang Y; GlaxoSmithKline, Collegeville, Pennsylvania, USA.
Stassek L; Evidera, Bethesda, Maryland, USA.
Wohlfeiler MB; AIDS Healthcare Foundation, Los Angeles, California, USA.
Sinclair GI; Prism Health North Texas, Dallas, Texas, USA.
Mena LA; University of Mississippi Medical Center, Jackson, Mississippi, USA.
Thedinger B; KC CARE Health Center, Kansas City, Missouri, USA.
Flamm JA; Kaiser Permanente Sacramento, Sacramento, California, USA.
Benson P; Be Well Medical Center, Berkley, California, USA.
Spreen WR; ViiV Healthcare, Durham, North Carolina, USA.; Pokaż więcej
Źródło:: Journal of the International AIDS Society [J Int AIDS Soc] 2022 Sep; Vol. 25 (9), pp. e26006.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Seropositivity*/drug therapy
HIV-1*
COVID-19 Drug Treatment*
Anti-Retroviral Agents/therapeutic use ; Delivery of Health Care ; Diketopiperazines ; Female ; Humans ; Male ; Pandemics ; Pyridones ; Rilpivirine/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Autorzy:: Czarnogorski M; ViiV Healthcare, Durham, North Carolina, USA.
Garris CP; ViiV Healthcare, Durham, North Carolina, USA.
Dalessandro M; ViiV Healthcare, Collegeville, Pennsylvania, USA.
D'Amico R; ViiV Healthcare, Durham, North Carolina, USA.
Nwafor T; ViiV Healthcare, Durham, North Carolina, USA.
Williams W; GSK, Collegeville, Pennsylvania, USA.
Merrill D; ViiV Healthcare, Durham, North Carolina, USA.
Wang Y; GSK, Collegeville, Pennsylvania, USA.
Stassek L; Evidera, Bethesda, Maryland, USA.
Wohlfeiler MB; AIDS Healthcare Foundation, Los Angeles, California, USA.
Sinclair GI; Prism Health North Texas, Dallas, Texas, USA.
Mena LA; University of Mississippi Medical Center, Jackson, Mississippi, USA.
Thedinger B; KC CARE Health Center, Kansas City, Missouri, USA.
Flamm JA; Kaiser Permanente Sacramento, Sacramento, California, USA.
Benson P; Be Well Medical Center, Berkley, California, USA.
Spreen WR; ViiV Healthcare, Durham, North Carolina, USA.; Pokaż więcej
Źródło:: Journal of the International AIDS Society [J Int AIDS Soc] 2022 Sep; Vol. 25 (9), pp. e26003.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
COVID-19 Drug Treatment*
Anti-Retroviral Agents/therapeutic use ; Delivery of Health Care ; Diketopiperazines ; Health Personnel ; Humans ; Pandemics ; Pyridones ; Rilpivirine/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Observational cohort study of rilpivirine (RPV) utilization in Europe.
Autorzy:: Cozzi-Lepri A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, Rowland Hill St, London, NW3 2PF, UK. .
Peters L; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pelchen-Matthews A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, Rowland Hill St, London, NW3 2PF, UK.
Neesgaard B; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
De Wit S; Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Johansen IS; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Edwards S; Mortimer Market Centre, Department of HIV, London, UK.
Stephan C; Infectious Diseases Unit, Goethe-University Hospital, Frankfurt, Germany.
Adamis G; 1St Department of Internal Medicine and Infectious Diseases Unit, General Hospital of Athens G. Gennimatas, Athens, Greece.
Staub T; Centre Hospitalier de Luxembourg, Service des Maladies Infectieuses, Luxembourg City, Luxembourg.
Zagalo A; Department of Infectious Diseases, Santa Maria University Hospital, Lisbon, Portugal.
Domingo P; Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
Elbirt D; Allergy, Immunology and HIV Unit | Kaplan, Medical Center, Rehovot, Israel.
Kusejko K; Division of Infectious Diseases, University Hospital Zürich, Zurich, Switzerland.
Brännström J; Department of Infectious Diseases, Venhälsan Södersjukhuset, Stockholm, Sweden.
Paduta D; Gomel Regional Centre for Hygiene, Gomel, Belarus.
Trofimova T; Novgorod Centre for AIDS Prevention and Control, Novgorod the Great, Russia.
Szlavik J; South-Pest Hospital Centre-National Institute for Infectiology and Haematology, Budapest, Hungary.
Zilmer K; West-Tallinn Central Hospital, Infectious Diseases Clinic, Talinn, Estonia.
Losso M; Hospital J.M. Ramos Mejia, Buenos Aires, Argentina.
Van Eygen V; Janssen Research & Development, Beerse, Belgium.
Pai H; Janssen Research & Development, Raritan, NJ, USA.
Lundgren J; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Mocroft A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, Rowland Hill St, London, NW3 2PF, UK.; CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Pokaż więcej
Corporate Authors:: EuroSIDA Study Group
Źródło:: AIDS research and therapy [AIDS Res Ther] 2022 Aug 06; Vol. 19 (1), pp. 38. Date of Electronic Publication: 2022 Aug 06.
Typ publikacji:: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/adverse effects
HIV Infections*/drug therapy
HIV-1*/genetics
Humans ; Rilpivirine/therapeutic use ; Treatment Outcome ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations.
Autorzy:: Cilento ME; Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA 30307, USA.
Ong YT; Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA 30307, USA.
Tedbury PR; Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA 30307, USA.
Sarafianos SG; Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA 30307, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2022 May 31; Vol. 14 (6). Date of Electronic Publication: 2022 May 31.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Drug Combinations ; Drug Interactions ; Humans ; Quality of Life ; Reverse Transcriptase Inhibitors/therapeutic use ; Rilpivirine/pharmacology ; Rilpivirine/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""rilpivirine"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji